SCHEMBL719877

SCHEMBL719877

COCc1nn(-c2cc(C(F)(F)F)ccn2)cc1C=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
ADRB1 P08588 1/20 0.36
ALDH1A1 P00352 3/20 0.34
GAA P10253 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
MAPT P10636 3/20 0.34
POLB P06746 1/20 0.34
EGLN2 Q96KS0 1/20 0.34
KDM4E B2RXH2 2/20 0.33
CYP2D6 P10635 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
CYP1A2 P05177 1/20 0.32
NOS3 P29474 1/20 0.32
NOS2 P35228 1/20 0.32
RXRA P19793 2/20 0.32
GRIN1 Q05586 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719795 0.83 SMN1; SMN2 (0.38) ALDH1A1GAAL3MBTL1MAPTPOLB
SCHEMBL27834233 0.82 ADRB1 (0.41) NPSR1ADRB1ALDH1A1GAAL3MBTL1
SCHEMBL719678 0.81 CFTR (0.41) NPSR1ADRB1ALDH1A1GAAL3MBTL1
SCHEMBL718319 0.81 ADRB1 (0.37) NPSR1ADRB1ALDH1A1GAAL3MBTL1
SCHEMBL719035 0.76 ACACB (0.35) HRH3ACACB
SCHEMBL16743011 0.73 ADRB1 (0.39) NPSR1ADRB1FFAR4MAPTEGLN2
SCHEMBL718365 0.72 PDE2A (0.36) NPSR1ADRB1FFAR4HRH3ACACB
SCHEMBL1803607 0.71 HDAC9 (0.34) NPSR1ALDH1A1L3MBTL1POLBKDM4E
SCHEMBL717944 0.71 MEN1 (0.42) L3MBTL1POLBKDM4ERXRAGRIN1
SCHEMBL716404 0.70 KMT2A (0.54) ALDH1A1GAAMAPTPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015641-B Heterocyclic compound TAKEDA PHARMACEUTICAL 2014-01-01 CN disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
CN-102015641-A Heterocyclic compound TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPSR1 2548/4885ADRB1 1358/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPSR1 2548/4885ADRB1 1358/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.